Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.
2.

Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.

Parsons K, Bernhardt B, Strickland B.

Ann Pharmacother. 2013 Feb;47(2):210-8. doi: 10.1345/aph.1R353. Epub 2013 Feb 5. Review.

PMID:
23386066
3.

New immunotherapeutic strategies for the treatment of neuroblastoma.

Croce M, Corrias MV, Rigo V, Ferrini S.

Immunotherapy. 2015;7(3):285-300. doi: 10.2217/imt.14.117. Review.

PMID:
25804480
5.
6.

Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma.

Szychot E, Peregud-Pogorzelski J, Wawryków P, Brodkiewicz A.

Postepy Hig Med Dosw (Online). 2016 Sep 28;70(0):1001-1004. Review.

7.

Dinutuximab: first global approval.

Dhillon S.

Drugs. 2015 May;75(8):923-7. doi: 10.1007/s40265-015-0399-5. Review. Erratum in: Drugs. 2015 Oct;75(15):1831. Drugs. 2015 Oct;75(15):1831.

PMID:
25940913
8.

Dinutuximab: A Review in High-Risk Neuroblastoma.

Hoy SM.

Target Oncol. 2016 Apr;11(2):247-53. doi: 10.1007/s11523-016-0420-2. Review.

PMID:
26891967
9.

Monoclonal antibodies and neuroblastoma.

Miraldi F.

Semin Nucl Med. 1989 Oct;19(4):282-94. Review.

PMID:
2678480
10.

Dinutuximab for maintenance therapy in pediatric neuroblastoma.

McGinty L, Kolesar J.

Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567. doi: 10.2146/ajhp160228. Review.

PMID:
28389455

Supplemental Content

Support Center